AR and pachyonychia congenita: Androgen receptor-axis-targeted therapies (ARATs)1, such as abiraterone or enzalutamide, are newer ADTs that are now commonly used for first-line treatment of metastatic castration-sensitive PC (mCSPC) as well as metastatic castration-resistant PC (mCRPC) [5, 6].